References
- Abahssain H1, Afchain P, Melas N, et al (2010). Chemotherapy in gallbladder carcinoma. Presse Med, 39, 1238-45. https://doi.org/10.1016/j.lpm.2010.09.002
- Agarwal SK, Munjal M, Koul R, et al (2014). Prospective evaluation of the quality of life of oral tongue cancer patients before and after the treatment. Ann Palliat Med, 3, 238-43.
- Alberts SR1, Sande JR, Foster NR, et al (2007). Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. J Gastrointest Cancer, 38, 87-94. https://doi.org/10.1007/s12029-008-9037-8
- Bajetta E, Celio L, Buzzoni R et al (2003). Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol, 14, 1543-8. https://doi.org/10.1093/annonc/mdg406
- Cripps C, Burnell M, Jolivet J, et al (1999). Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol, 10, 1175-9. https://doi.org/10.1023/A:1008372529239
- De Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47. https://doi.org/10.1200/JCO.2000.18.16.2938
- Essam Eldin N1, Elnahas HM, Mahdy MA, et al (2015). Liposomal pemetrexed: formulation, characterization and in vitro cytotoxicity studies for effective management of malignant pleural mesothelioma. Biol Pharm Bull, 38, 461-9. https://doi.org/10.1248/bpb.b14-00769
- Garin A, Manikhas A, Biakhov M, et al (2008). A phase II study of pemetrexed and carboplatin in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat, 110, 309-15. https://doi.org/10.1007/s10549-007-9722-5
- Giovannetti E, Mey V, Danesi R, et al (2004). Synergistic cytotoxicity and pharmacogenetics of gemcitabine andpemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res, 10, 2936-43. https://doi.org/10.1158/1078-0432.CCR-03-0520
- Hanauske AR, Chen V, Paoletti P, et al (2001). Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. The Oncologist, 6, 363-373. https://doi.org/10.1634/theoncologist.6-4-363
- Hellner K, Munger K (2011). Human papillomaviruses as therapeutic targets in human cancer. J Clin Oncol, 29, 1785-94. https://doi.org/10.1200/JCO.2010.28.2186
- Hochster HS (2004). The role of pemetrexed in the treatment of gastrointestinal malignancy. Clin Colorectal Cancer, 4, 190-5. https://doi.org/10.3816/CCC.2004.n.019
- Huang XE, Hirose K, Wakai K, et al (2004). Comparison of lifestyle risk factors by family history for gastric, breast, lung and colorectal cancer. Asian Pac J Cancer Prev, 5, 419-27.
- Jatoi A, Soori G, Foster NR, et al (2010). Phase II study of preoperative pemetrexed, carboplatin, and radiation followed by surgery for locally advanced esophageal cancer and gastroesophageal junction tumors. J Thorac Oncol, 5, 1994-8. https://doi.org/10.1097/JTO.0b013e3181fb5c3e
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- John W, Picus J, Blanke CD, et al (2000). Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer, 88, 1807-13. https://doi.org/10.1002/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L
- Katipamula R, Jatoi A, Foster NR, et al (2008). Pemetrexed, carboplatin, and concomitant radiation followed by surgery for locally advanced esophageal cancer: results of a planned interim toxicity analysis of north central cancer treatment group study N044E. Clin Med Oncol, 2, 223-5.
- Leemans CR, Braakhuis BJ, Brakenhoff RH (2010). The molecular biology of head and neck cancer. Nat Rev Cancer, 11, 9-22.
- Li BS, Gong HY, Huang W, et al (2011). Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and pemetrexed, cisplatin for locally advanced esophageal squamous cell carcinoma. Dis Esophagus, b, 251-7.
- Liu J, Huang XE, Feng JF, (2014). Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC). Asian Pac J Cancer Prev, 15, 6587-90. https://doi.org/10.7314/APJCP.2014.15.16.6587
- Lorusso D, Ferrandina G, Pignata S, et al (2010). Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrentcarcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol, 21, 61-6. https://doi.org/10.1093/annonc/mdp266
- Louvet C, de Gramont A (2004). Pemetrexed in advanced colorectal cancer. Oncology (Williston Park), 18, 56-62.
- Matulonis UA, Horowitz NS, Campos SM, et al (2008). Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clinical Oncology, 26, 5761-6. https://doi.org/10.1200/JCO.2008.17.0282
- Miyazaki T, Sohda M, Tanaka N, et al (2013). Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer. Cancer Chemother Pharmacol, 71, 853-7. https://doi.org/10.1007/s00280-013-2076-2
- Parkin DM, Bray F, Ferlay J, et al (2004). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
- Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
- Price KA, Cohen EE, (2012). Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol, 13, 35-46. https://doi.org/10.1007/s11864-011-0176-y
- Robert NJ, Conkling PR, O'Rourke MA, et al (2011). Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat, 126, 101-8. https://doi.org/10.1007/s10549-010-1286-0
- Robert NJ, Conkling PR, O'Rourke MA, et al (2011). Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat, 126, 101-8. https://doi.org/10.1007/s10549-010-1286-0
- Rollins KD, Lindley C, (2005). Pemetrexed: a multitargeted antifolate. Clin Ther, 27, 1343-82. https://doi.org/10.1016/j.clinthera.2005.09.010
- Scagliotti GV, Parikh P, von Pawel J, et al (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin pluspemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 26, 3543-51. https://doi.org/10.1200/JCO.2007.15.0375
- Sehouli J, Camara O, Mahner S, (2010). A phase I trial of pemetrexed plus carboplatin in recurrent ovarian cancer. Cancer Chemotherapy Pharmacol, 66, 861-8. https://doi.org/10.1007/s00280-009-1230-3
- Seiwert TY, Connell PP, Mauer AM, et al (2007). A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res, 13, 515-22. https://doi.org/10.1158/1078-0432.CCR-06-1058
- Siegel R, Naishadham D, Jemal A, (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. https://doi.org/10.3322/caac.21166
- Vaughan S, Coward JI, Bast RC Jr, et al (2011). Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer, 11, 719-25. https://doi.org/10.1038/nrc3144
- Wu XY, Huang XE, You SX, et al (2013). Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. Asian Pac J Cancer Prev, 14, 2019-22. https://doi.org/10.7314/APJCP.2013.14.3.2019
- Zhang LQ, Xu XS, Wan Y, et al (2015). Prognostic implications of estrogen receptor 1 and vascular endothelial growth factor A expression in primary gallbladder carcinoma. World J Gastroenterol, 21, 1243-50. https://doi.org/10.3748/wjg.v21.i4.1243
Cited by
- Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
- A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485